Compare DTCK & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DTCK | ASBP |
|---|---|---|
| Founded | 1999 | 2021 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 7.6M |
| IPO Year | 2023 | N/A |
| Metric | DTCK | ASBP |
|---|---|---|
| Price | $0.29 | $1.87 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 9.0M | 1.4M |
| Earning Date | 12-23-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $160,529,000.00 | $1,941.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.43 | N/A |
| 52 Week Low | $0.23 | $1.66 |
| 52 Week High | $6.89 | $632.00 |
| Indicator | DTCK | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 41.71 | 81.80 |
| Support Level | $0.30 | $1.71 |
| Resistance Level | $0.33 | $2.02 |
| Average True Range (ATR) | 0.03 | 0.13 |
| MACD | 0.02 | 0.21 |
| Stochastic Oscillator | 3.33 | 76.19 |
Davis Commodities Ltd is an agricultural commodity trading company based in Singapore, which specializes in the trading of three main categories of agricultural commodities, namely sugar, rice, and oil and fat products. It distributes agricultural commodities to various markets, including Asia, Africa, and the Middle East. The company also provides customers of commodity offerings with complementary, ancillary services such as warehouse handling and storage, and logistics services. The Company operates across four main segments: the sale of sugar, rice, oil, and fat products, and others. Among these, the sale of sugar stands out as the primary revenue generator, contributing significantly to the company's overall income.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.